




## Tafenoquine

Revised: May 1, 2019.

CASRN: 106635-80-7



## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the use of tafenoquine during breastfeeding. Tafenoquine can cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. If tafenoquine is needed by the mother, testing the mother and infant for G6PD deficiency is required before the drug is given. Because the half-life of tafenoquine averages 15 days, the manufacturer recommends that breastfeeding should not breastfeed for 3 months after the dose if the infant is G6PD deficient.

### Drug Levels

Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## Alternate Drugs to Consider

Primaquine

## Substance Identification

### Substance Name

Tafenoquine

### CAS Registry Number

106635-80-7

### Drug Class

Breast Feeding

Lactation

Anti-Infective Agents

Antiparasitic Agents

Antimalarials

Antiprotozoal Agents